|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | 非胰岛素依赖型糖尿病冠状动脉疾病的危险因素:英国糖尿病前瞻性研究(UKPDS:23)显示文摘目的:评价2型糖尿病患者冠状动脉疾病的基线危险因素。设计:对2 693例资料完整的患者进行年龄和性别调整的逐步选择过程分析,以确定哪些冠状动脉疾病的危险因素应纳入 Cox 比例风险模型。对象:3 055例白人患者,平均年龄52岁,均新近诊断为2型糖尿病,且无动脉粥样硬化相关疾病的证据。平均随访期7.9年。335例患者于10年内出现冠状动脉疾病。结局评定:具有明确异常心电图的心绞痛、致死或非致死性心肌梗塞。结果:冠状动脉疾病与低密度脂蛋白胆固醇浓度升高、高密度脂蛋白胆固醇浓度降低、甘油三酯浓度升高、高血红蛋白 A_(1c)、高收缩压、高空腹血糖以及吸烟史密切相关。低密度脂蛋白胆固醇较高1/3对较低1/3区间的估计风险比为2.26(95%可信区间为1.70~3.00),高密度脂蛋白胆固醇为0.55(0.41~0.73),血红蛋白 A_(1c)为1.52(1.15~2.01),收缩压为1.82(1.34~2.47)。吸烟者的估计风险比为1.41(1.06~1.88)。结论:2型糖尿病患者中,存在冠状动脉疾病潜在的、可变的5种危险因素的交叉重叠影响。它们是低密度脂蛋白胆固醇浓度升高、高密度脂蛋白胆固醇浓度降低、高血压、高血糖和吸烟。 | R C Turner H Millns H A W Neil I M Stratton S E Manley D R Matthews R R Holman 赵维纲 | 1998 | 英国医学杂志中文版1998，0，3： | 11 |
| 2 | Role of endoscopy in the management of primary sclerosing cholangitis显示文摘Primary sclerosing cholangitis(PSC) is a rare but prominent fibroinflammatory cholangiopathy which can affect individuals of essentially any age. It carries a median survival of 15-20 years, regardless of age at diagnosis, and is a foremost risk factor for cholangiocarcinoma. Given the chronic and progressive nature of PSC, its inherent risk for biliary tract and other complications, and the paucity of effective pharmacotherapies, endoscopy plays a major role in the care of many patients with this disorder. In this review, we discuss the endoscopic management of PSC, including established and evolving approaches to the diagnosis and treatment of its benign as well as malignant sequelae. Owing to the rarity of PSC and dearth of high-quality evidence, we propose pragmatic approaches based on both currently available data and expert opinion. | Neil Bharat Marya James H Tabibian | 2019 | World Journal of Gastrointestinal Endoscopy2019，11，2： | 4 |
| 3 | Evaluation of a locked nucleic acid form of antisense oligo targeting HIF-1α in advanced hepatocellular carcinoma显示文摘BACKGROUND Hypoxia-inducible factor 1α(HIF-1α) is a gene that regulates tumor survival,neovascularization and invasion. Overexpression of HIF-1α correlates with poor prognosis in hepatocellular carcinoma(HCC). RO7070179 is a HIF-1α inhibitor that decreases HIF-1α mRNA and its downstream targets, it could be a potential treatment in HCC.AIM To evaluate safety and preliminary activity of RO7070179 in patients with previously treated HCC, with focus on a patient with prolonged response to RO7070179.METHODS In the preclinical study of RO7070179 in a HCC xenograft model, the mice wereseparated into 4 groups with each group received doses of 0, 3, 10 and 30 mg/kg for total 10 doses. HCC patients who failed at least one line of systemic treatment,received RO7070179 as a weekly infusion, each cycle is 6 wk. We evaluated the safety and HIF-1α mRNA levels of RO7070179.RESULTS Preclinical evaluation of RO7070179 in orthotopic HCC xenograft model showed no significant differences in HCC tumor weight between the 3 and 10 mg/kg groups. However, dose of 10 mg/kg of RO7070179, has shown 76% reduction of the amount of HIF-1α mRNA in HCC tissue. In the phase 1 b study of RO7070179 in previously treated HCC patients, 8 out of 9 were evaluable: 1 achieved PR and1 SD. The patient with PR responded after 2 cycles treatments, which has been maintained for 12 cycles. This patient also showed reduction in perfusion of dynamic contrast-enhanced magnetic resonance imaging(DCE-MRI) after 1 cycle of treatment. After 1 cycle of treatment, both patients with PR and SD showed decrease in HIF-1α mRNA at the root of biopsies(each biopsy was divided into 2 specimens, the tip and the root).CONCLUSION RO7070179 can reduce HIF-1α mRNA level in HCC patients with SD or PR. It is well tolerated at 10 mg/kg, with transaminitis as the dose of increased toxicity.This study indicates that RO7070179 might benefit HCC patients, and an early signal for clinical benefit can potentially be predicted through changes in either m RNA level or DCE-MRI within 1 cycle of therapy. | Jennifer Wu Merly Contratto Krishna P Shanbhogue Gulam A Manji Bert H O'Neil Anne Noonan Robert Tudor Ray Lee | 2019 | World Journal of Clinical Oncology2019，10，3： | 2 |
| 4 | Liver involvement in the drug reaction,eosinophilia,and systemic symptoms syndrome显示文摘First described in 1996,the drug reaction,eosinophilia,and systemic symptoms syndrome(DReSS) is considered,along with Stevens-Johnson syndrome and toxic epidermal necrolysis,a severe cutaneous drug reaction. It is characterized by the presence of a maculopapular erythematous skin eruption,fever,lymphadenopathy,influenza-like symptoms,eosinophilia,and visceral involvement such as hepatitis,pneumonitis,myocarditis,pericarditis,nephritis,and colitis. The prognosis of patients with DReSS is related to the severity of visceral involvement. The mortality ranges from approximately 5% to 10%,and death is mainly due to liver failure,which is also the organ most commonly involved in this syndrome. Although it was previously hypothesized in 1994,DReSS syndrome can lead to reactivation of one or more human herpesvirus family members. Now being included as diagnostic criteria in a proposed diagnostic score system,this reactivation can be detected up to 2-3 wk after DReSS syndrome onset. Other causes of mortality in DReSS syndrome include myocardial or pulmonary lesions and hemophagocytosis. We reviewed the literature of previously reported case-series of DReSS and liver involvement,highlighting the pattern of liver damage,the treatment used,and the outcome. | Sylvia A Martinez-Cabriales Neil H Shear Emmanuel I Gonzalez-Moreno | 2019 | World Journal of Clinical Cases2019，7，6： | 2 |
| 5 | Marketing Productivity, Marketing Audits and Systems for Marketing Performance Assessment显示文摘 | NEIL A M BRUCE H C | 2002 | Journal of Business Research2002，，55： | 1 |
| 6 | Association of systolic blood pressure with macrovascular and microvascular complications on type 2 diabetes (UKPDS 36 ): prospective observational study 显示文摘 | ADLER A I STRATrON I M NEIL H A | 2000 | BMJ2000，321，： | 1 |
| 7 | Association of glycaemia with macrovascular and micro-vascular complications of type 2 diabetes (UKPDS 35): prospective observational study 显示文摘 | Stratton I M Adler A I Neil H A | 2000 | BMJ2000，321，： | 1 |
| 8 | Trinexapac-ethyl influence on cell membrane thermostability of Kentucky bluegrass leaf tissue显示文摘 | Neil L H Garald L H Roch E G | 2002 | Scinesia Horticulturae2002，92，： | 1 |
| 9 | Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes(UKPDS 35):prospective observational study显示文摘 | Stratton I M Adler A I Neil H A | | 0，，7258： | 1 |
| 10 | Analytical applications of acid potassium permanganate as a chemiluminescence reagent 显示文摘 | Benjamin J H Neil W | 2001 | Analytica Chimica Acta2001，445，1： | 1 |
| 11 | Temkin vacuum electronics high power terahertz sources 显示文摘 | John H Booske Richard J Dobbs Colin D Joye Carol L Kory George R Neil Gunn-sik Park Jaehun Park Richard J | 2011 | IEEE transactions on terahertz science and technolo- gy2011，1，1： | 1 |
| 12 | Structural basis of a phololropinlight switch显示文摘 | Harper S M Neil L C Gardner K H | 2003 | Science2003，301，5639： | 1 |
| 13 | risk factors for coronary artery disease in non insulin dependent diabetes mellitus,united kingdom prospective diabetes study显示文摘 | Turner rc milins h neil ha | | 0，，： | 1 |
| 14 | Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus(UKPDS 23)显示文摘 | Turner RC Millns H Neil HAW | 1998 | BMJ1998，316，7134： | 1 |
| 15 | Effeets of furoquinoline alkaloids on the growth and feeding of two polyphagous lepidopterans显示文摘 | Tara E Saekett G H Neil Towers Murray B Isman | 2007 | Chemoecology2007，17，： | 1 |
| 16 | Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus:United Kingdom prospective diabetes study (UKPDS:23)显示文摘 | Turner RC Millns H Neil HA | 1998 | BMJ1998，316，7134： | 1 |
| 17 | Association of glycaemia with macrovascular and microvaseular complications of type 2 diabetes (UKPDS 35) : prospective observational study显示文摘 | STRAT'I'ON I M ADLER A I NEIL H A | 2000 | BMJ2000，321，7258： | 1 |
| 18 | Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial显示文摘 | Helen M Colhoun D John Betteridge Paul N Durrington Graham A Hitman H Andrew W Neil Shona J Livingstone Margaret J Thomason Michael I Mackness Valentine Charlton-Menys John H Fuller | 2004 | The Lancet . 2004 (9435)2004，，9435： | 1 |
| 19 | Risk factors for coronary artery disease in noninsulin dependent diabetes mellitus:United Kingdom Prospective Diabetes Study(UKPD:23)显示文摘 | Turner RC Milns H Neil HA | 1998 | BMJ1998，316，7134： | 1 |
| 20 | Spray drying显示文摘 | Neil H M | 2001 | Food Tech2001，65，4： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员